Abstract:Encoded by PTPN11 , the Src-homology 2 domain-containing phosphatase 2 (SHP2) integrates signals from various membrane-bound receptors such as receptor tyrosine kinases (RTKs), cytokine and integrin receptors and thereby promotes cell survival and proliferation. Activating mutations in the PTPN11 gene may trigger signaling pathways leading to the development of hematological malignancies, but are rarely found in solid tumors. Yet, aberrant SHP2 expression or activation has implications in the development, progression and metastasis of many solid tumor entities. SHP2 is involved in multiple signaling cascades, including the RAS-RAF-MEK-ERK-, PI3K-AKT-, JAK-STAT- and PD-L1/PD-1- pathways. Although not mutated, activation or functional requirement of SHP2 appears to play a relevant and context-dependent dichotomous role. This mostly tumor-promoting and infrequently tumor-suppressive role exists in many cancers such as gastrointestinal tumors, pancreatic, liver and lung cancer, gynecological entities, head and neck cancers, prostate cancer, glioblastoma and melanoma. Recent studies have identified SHP2 as a potential biomarker for the prognosis of some solid tumors. Based on promising preclinical work and the advent of orally available allosteric SHP2-inhibitors early clinical trials are currently investigating SHP2-directed approaches in various solid tumors, either as a single agent or in combination regimes. We here provide a brief overview of the molecular functions of SHP2 and collate current knowledge with regard to the significance of SHP2 expression and function in different solid tumor entities, including cells in their microenvironment, immune escape and therapy resistance. In the context of the present landscape of clinical trials with allosteric SHP2-inhibitors we discuss the multitude of opportunities but also limitations of a strategy targeting this non-receptor protein tyrosine phosphatase for treatment of solid tumors.

A patent review of SHP2 allosteric inhibitors (2018-present)

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

Advances in SHP2 Tunnel Allosteric Inhibitors and Bifunctional Molecules

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Targeting SHP2 As a Promising Strategy for Cancer Immunotherapy

Cross the Undruggable Barrier, the Development of SHP2 Inhibitors: from Catalytic Site Inhibitors to Allosteric Inhibitors

Strategies to overcome drug resistance using SHP2 inhibitors

Therapeutic Potential of Targeting SHP2 in Human Developmental Disorders and Cancers

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull's eye for targeted therapy?

Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment

A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma

Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis

Study on the allosteric activation mechanism of SHP2 <i>via</i> elastic network models and neural relational inference molecular dynamics simulation

Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment

Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)